Slenyto prolonged-release tablets are a new licensed melatonin product.

Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. The recommended starting dose is 2 mg of Slenyto. If an inadequate response has been observed, the dose should be increased to 5 mg, with a maximal dose of 10 mg. Slenyto should be taken once daily, 0.5-1 hour before bedtime and with or after food

Slenyto is available as 1mg and 5mg prolonged release tablets.

The Summary of Product Characteristics can be found at; here

Further information can be obtained by contacting your ward pharmacist or the Medicines Information Hotline on 0843 506 5554